A partially purified outer membrane protein VirB9-1 for low-cost nanovaccines against Anaplasma marginale

Zhao, Liang, Cavallaro, Antonino S., Wibowo, David, Zhang, Bing, Zhang, Jun, Mitter, Neena, Yu, Chengzhong, Zhao, Chun-Xia and Middelberg, Anton P. J. (2017) A partially purified outer membrane protein VirB9-1 for low-cost nanovaccines against Anaplasma marginale. Vaccine, 35 1: 77-83. doi:10.1016/j.vaccine.2016.11.037


Author Zhao, Liang
Cavallaro, Antonino S.
Wibowo, David
Zhang, Bing
Zhang, Jun
Mitter, Neena
Yu, Chengzhong
Zhao, Chun-Xia
Middelberg, Anton P. J.
Title A partially purified outer membrane protein VirB9-1 for low-cost nanovaccines against Anaplasma marginale
Formatted title
A partially purified outer membrane protein VirB9-1 for low-cost nanovaccines against Anaplasma marginale
Journal name Vaccine   Check publisher's open access policy
ISSN 0264-410X
1873-2518
Publication date 2017-01-03
Year available 2016
Sub-type Article (original research)
DOI 10.1016/j.vaccine.2016.11.037
Open Access Status Not Open Access
Volume 35
Issue 1
Start page 77
End page 83
Total pages 7
Place of publication London, United Kingdom
Publisher Elsevier
Language eng
Subject 1313 Molecular Medicine
2400 Immunology and Microbiology
3400 Veterinary
2739 Public Health, Environmental and Occupational Health
2725 Infectious Diseases
Abstract Anaplasma marginale is a devastating tick-borne pathogen causing anaplasmosis in cattle and results in significant economic loss to the cattle industry worldwide. Currently, there is no widely accepted vaccine against A. marginale. New generation subunit vaccines against A. marginale, which are much safer, more efficient and cost-effective, are in great need. The A. marginale outer membrane protein VirB9-1 is a promising antigen for vaccination. We previously have shown that soluble recombinant VirB9-1 protein can be expressed and purified from Escherichia coli and induce a high level of humoral and cellular immunity in mice. In this study, we re-formulated the nanovaccines using the partially-purified VirB9-1 protein as the antigen and hollow nano-size silica vesicles (SV-100) as the adjuvant. We simplified the purification method to obtain the partially-purified antigen VirB9-1 with a six-fold higher yield. The new formulations using the partially-purified VirB9-1 protein achieved higher antibody and cell-mediated immune responses compared to the purified ones. This finding suggests that the partially-purified VirB9-1 protein performs better than the purified ones in the vaccination against A. marginale, and a certain level of contaminants in the protein antigen can be self-adjuvant and boost immunogenicity together with the nanoparticle adjuvant. This may lead to finding a “Goldilocks” level of contaminants. The new nanovaccine formulation using partially-purified antigens along with nanoparticle adjuvants offers an alternative strategy for making cheaper veterinary vaccines.
Formatted abstract
Anaplasma marginale is a devastating tick-borne pathogen causing anaplasmosis in cattle and results in significant economic loss to the cattle industry worldwide. Currently, there is no widely accepted vaccine against A. marginale. New generation subunit vaccines against A. marginale, which are much safer, more efficient and cost-effective, are in great need. The A. marginale outer membrane protein VirB9-1 is a promising antigen for vaccination. We previously have shown that soluble recombinant VirB9-1 protein can be expressed and purified from Escherichia coli and induce a high level of humoral and cellular immunity in mice. In this study, we re-formulated the nanovaccines using the partially-purified VirB9-1 protein as the antigen and hollow nano-size silica vesicles (SV-100) as the adjuvant. We simplified the purification method to obtain the partially-purified antigen VirB9-1 with a six-fold higher yield. The new formulations using the partially-purified VirB9-1 protein achieved higher antibody and cell-mediated immune responses compared to the purified ones. This finding suggests that the partially-purified VirB9-1 protein performs better than the purified ones in the vaccination against A. marginale, and a certain level of contaminants in the protein antigen can be self-adjuvant and boost immunogenicity together with the nanoparticle adjuvant. This may lead to finding a “Goldilocks” level of contaminants. The new nanovaccine formulation using partially-purified antigens along with nanoparticle adjuvants offers an alternative strategy for making cheaper veterinary vaccines.
Keyword Anaplasma marginale
Partially-purified antigens
Aggregates
Endotoxin
Silica vesicles
Immunogenicity
Q-Index Code C1
Q-Index Status Provisional Code
Grant ID 013936_471
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Mon, 28 Nov 2016, 20:08:59 EST by David Wibowo on behalf of Aust Institute for Bioengineering & Nanotechnology